Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31696726 | 0.74 | KMT2A (0.41) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL4920290 | 0.74 | HDAC1 (0.72) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL24472759 | 0.73 | HDAC6 (0.77) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL22482907 | 0.73 | HDAC6 (0.54) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL8256683 | 0.72 | ALDH1A1 (0.51) | HDAC6HDAC1 | |
| SCHEMBL2409640 | 0.72 | HDAC1 (0.62) | HDAC6HDAC1HDAC8HDAC2 | |
| SCHEMBL5615881 | 0.71 | MMP13 (0.82) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL4916915 | 0.71 | HDAC1 (0.59) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL19631373 | 0.71 | HDAC6 (0.68) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL22040077 | 0.71 | HDAC6 (0.63) | HDAC6HDAC1HDAC8HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2008-10-30 | — | — | US | disclosed |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | AOC2, AOC3, AOC1 | HDAC6 2092/4885HDAC1 563/4885HDAC8 3399/4885 |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | AOC2, AOC3, AOC1 | HDAC6 2060/4885HDAC1 622/4885HDAC8 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.